Cargando…
The International Guideline Evaluation Screening Tool (IGEST): development and validation
BACKGROUND: Guideline adaptation provides an important alternative to de novo guideline development by making the process more efficient and reducing unnecessary duplication. The quality evaluation of international guidelines is an essential part of the adaptation process. The study aims at describi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088113/ https://www.ncbi.nlm.nih.gov/pubmed/35538433 http://dx.doi.org/10.1186/s12874-022-01618-5 |
_version_ | 1784704299686690816 |
---|---|
author | D’angelo, Daniela Coclite, Daniela Napoletano, Antonello Gianola, Silvia Castellini, Greta Latina, Roberto Iacorossi, Laura Fauci, Alice Josephine Iannone, Primiano |
author_facet | D’angelo, Daniela Coclite, Daniela Napoletano, Antonello Gianola, Silvia Castellini, Greta Latina, Roberto Iacorossi, Laura Fauci, Alice Josephine Iannone, Primiano |
author_sort | D’angelo, Daniela |
collection | PubMed |
description | BACKGROUND: Guideline adaptation provides an important alternative to de novo guideline development by making the process more efficient and reducing unnecessary duplication. The quality evaluation of international guidelines is an essential part of the adaptation process. The study aims at describing the development and validation of a new tool to screen trustworthy Clinical Practice Guidelines (CPGs) for their adoption/adaption: the International Guideline Evaluation Screening Tool (IGEST). METHODS: The process of developing the IGEST involved two main phases: 1) tool development and 2) content validation. The tool development phase comprised three stages, where the scope of the IGEST was defined and the item pool was generated and refined. The content validation was performed through the computation of a content validity index (CVI) based on the opinions of an expert panel. RESULTS: All the items obtained a CVI >0.78, which resulted in the validation of the instrument. The final instrument comprised four preliminary conditions and 12 criteria organised into three dimensions: (i) the management of conflict of interest; (ii) the quality of evidence and the coherence between evidence and recommendations; and (iii) the panel composition. CONCLUSION: The IGEST showed good content validity for assessing the quality of international guidelines. Using the new tool to select trustworthy guidelines might increase the likelihood that international clinical practice guidelines will be adopted/adapted to the local context by allowing a quick screening of existing guidelines trustworthiness and providing an acceptability threshold that supports the decision-making process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-022-01618-5. |
format | Online Article Text |
id | pubmed-9088113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90881132022-05-11 The International Guideline Evaluation Screening Tool (IGEST): development and validation D’angelo, Daniela Coclite, Daniela Napoletano, Antonello Gianola, Silvia Castellini, Greta Latina, Roberto Iacorossi, Laura Fauci, Alice Josephine Iannone, Primiano BMC Med Res Methodol Research BACKGROUND: Guideline adaptation provides an important alternative to de novo guideline development by making the process more efficient and reducing unnecessary duplication. The quality evaluation of international guidelines is an essential part of the adaptation process. The study aims at describing the development and validation of a new tool to screen trustworthy Clinical Practice Guidelines (CPGs) for their adoption/adaption: the International Guideline Evaluation Screening Tool (IGEST). METHODS: The process of developing the IGEST involved two main phases: 1) tool development and 2) content validation. The tool development phase comprised three stages, where the scope of the IGEST was defined and the item pool was generated and refined. The content validation was performed through the computation of a content validity index (CVI) based on the opinions of an expert panel. RESULTS: All the items obtained a CVI >0.78, which resulted in the validation of the instrument. The final instrument comprised four preliminary conditions and 12 criteria organised into three dimensions: (i) the management of conflict of interest; (ii) the quality of evidence and the coherence between evidence and recommendations; and (iii) the panel composition. CONCLUSION: The IGEST showed good content validity for assessing the quality of international guidelines. Using the new tool to select trustworthy guidelines might increase the likelihood that international clinical practice guidelines will be adopted/adapted to the local context by allowing a quick screening of existing guidelines trustworthiness and providing an acceptability threshold that supports the decision-making process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-022-01618-5. BioMed Central 2022-05-10 /pmc/articles/PMC9088113/ /pubmed/35538433 http://dx.doi.org/10.1186/s12874-022-01618-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research D’angelo, Daniela Coclite, Daniela Napoletano, Antonello Gianola, Silvia Castellini, Greta Latina, Roberto Iacorossi, Laura Fauci, Alice Josephine Iannone, Primiano The International Guideline Evaluation Screening Tool (IGEST): development and validation |
title | The International Guideline Evaluation Screening Tool (IGEST): development and validation |
title_full | The International Guideline Evaluation Screening Tool (IGEST): development and validation |
title_fullStr | The International Guideline Evaluation Screening Tool (IGEST): development and validation |
title_full_unstemmed | The International Guideline Evaluation Screening Tool (IGEST): development and validation |
title_short | The International Guideline Evaluation Screening Tool (IGEST): development and validation |
title_sort | international guideline evaluation screening tool (igest): development and validation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088113/ https://www.ncbi.nlm.nih.gov/pubmed/35538433 http://dx.doi.org/10.1186/s12874-022-01618-5 |
work_keys_str_mv | AT dangelodaniela theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT coclitedaniela theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT napoletanoantonello theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT gianolasilvia theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT castellinigreta theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT latinaroberto theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT iacorossilaura theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT faucialicejosephine theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT iannoneprimiano theinternationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT dangelodaniela internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT coclitedaniela internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT napoletanoantonello internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT gianolasilvia internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT castellinigreta internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT latinaroberto internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT iacorossilaura internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT faucialicejosephine internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation AT iannoneprimiano internationalguidelineevaluationscreeningtooligestdevelopmentandvalidation |